U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE® (lazertinib) – Johnson & Johnson

1. U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE® (lazertinib)  Johnson & Johnson
2. J&J scores FDA nod for subcutaneous lung cancer shot, sharpening its challenge to Tagrisso  Fierce Pharma
3. J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant  Yahoo Finance
4. Rybrevant Faspro Receives FDA Approval for All Amivantamab Indications  Medical Professionals Reference
5. Genmab partner gets FDA approval for expanded use of lung cancer drug  medwatch.com

Source link